MedPath

Melatonin add on anti epileptic drug

Phase 3
Conditions
seizure.
Epilepsy and recurrent seizures
Registration Number
IRCT20101209005352N4
Lead Sponsor
Zanjan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Age range 18_45 years
1_4 general idiopathic tonic-clonic seizure attacks in the last 4 months
Patients with a therapeutic level anti epileptic drugs

Exclusion Criteria

Patient dissatisfaction
Patients are intubation
Loss of consciousness
Patients without a therapeutic level anti epileptic drugs

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Frequency and severity of seizures. Timepoint: After 8 and 18 weeks of treatment. Method of measurement: According to Chalfont questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath